Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab + PK-dosed Melphalan vs BSA-dosed Melphalan in Multiple Myeloma Patients Undergoing ASCT
NCT06679829Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Started Nov 2024; status: recruiting.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06679829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06679829.